OVOCA BIO PLC (OVXA.I) Stock Price & Overview
DUB:OVXA • IE00B4XVDC01
Current stock price
The current stock price of OVXA.I is 0.0105 EUR. Today OVXA.I is down by -8.7%. In the past month the price decreased by -57.14%. In the past year, price decreased by -93.4%.
OVXA.I Key Statistics
- Market Cap
- 928.83K
- P/E
- N/A
- Fwd P/E
- N/A
- EPS (TTM)
- -0.06
- Dividend Yield
- N/A
OVXA.I Stock Performance
OVXA.I Stock Chart
OVXA.I Technical Analysis
ChartMill assigns a technical rating of 1 / 10 to OVXA.I. When comparing the yearly performance of all stocks, OVXA.I is a bad performer in the overall market: 98.78% of all stocks are doing better.
OVXA.I Fundamental Analysis
ChartMill assigns a fundamental rating of 2 / 10 to OVXA.I. OVXA.I has a great financial health rating, but its profitability evaluates not so good.
OVXA.I Earnings
OVXA.I Forecast & Estimates
OVXA.I Groups
Sector & Classification
OVXA.I Financial Highlights
Over the last trailing twelve months OVXA.I reported a non-GAAP Earnings per Share(EPS) of -0.06. The EPS increased by 9.01% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -151.63% | ||
| ROE | -210% | ||
| Debt/Equity | 0 |
OVXA.I Ownership
OVXA.I Competitors/Peers
| Symbol | Company Name | Technical Rating | Fundamental Rating | FPE | Market Cap |
|---|---|---|---|---|---|
| SNW | SANOFI | 9.58 | 99.52B | ||
| SAN | SANOFI | 9.59 | 99.435B | ||
| 1SAN | SANOFI | 9.56 | 99.241B | ||
| 1MRK | MERCK KGAA | 15 | 51.435B | ||
| UNC | UCB SA | 24.99 | 51.331B | ||
| MRK | MERCK KGAA | 15 | 51.108B | ||
| UCB | UCB SA | 24.42 | 50.378B | ||
| BAYN | BAYER AG-REG | 9.37 | 40.633B | ||
| 1BAYN | BAYER AG-REG | 9.37 | 40.515B | ||
| IPN | IPSEN | 12.84 | 13.619B | ||
| REC | RECORDATI INDUSTRIA CHIMICA | 16.85 | 10.488B | ||
| TUB | FINANCIERE DE TUBIZE | N/A | 9.89B | ||
| VIRP | VIRBAC SA | 17.84 | 3.18B |
Related stock screener links
View all stocks in the Pharmaceuticals Industry | View all stocks in the Health Care Sector | View all stocks on the Euronext Dublin Exchange | Find stocks with similar TA and Setup ratings on the EuroNext exchanges | Find stocks with similar Fundamental rating on the EuroNext exchanges | Find the competitors with the best technical ratings on the EuroNext exchanges | Find the competitors with the best fundamentals on the EuroNext exchanges | Find the competitors with the best valuation on the EuroNext exchanges | Find the competitors with the best dividend on the EuroNext exchanges | Find the competitors with the best analyst ratings on the EuroNext exchanges
About OVXA.I
Company Profile
Ovoca Bio Plc is a clinical-stage biopharmaceutical company, which engages in the women's health, clinical development and commercial planning of BP-101, and novel treatment for women with hypoactive sexual desire disorder (HSDD). The firm is developing Orenetide, a novel medicinal treatment for premenopausal women with hypoactive sexual desire disorder (HSDD). The company is focused on women’s health and identifying novel candidates in areas of high unmet medical need. The Company’s lead product, Orenetide (BP-101), is a novel synthetic peptide for the treatment of HSDD and is conveniently administered through a nasal spray. The spray delivers the drug to olfactory and trigeminal nerves in the nasal cavity where the drug accumulates in the olfactory bulb and further in the brain. The company is also developing a new treatment for women affected by low libido or sex drive. The company owns a patent portfolio that provides effective protection of its technology. The firm operates in Ireland, the United Kingdom and Russia.
Company Info
IPO: 1987-04-21
OVOCA BIO PLC
17 Pembroke Street, Upper
DUBLIN DUBLIN IE
Employees: 5
Phone: 35316619819
OVOCA BIO PLC / OVXA.I FAQ
Can you describe the business of OVOCA BIO PLC?
Ovoca Bio Plc is a clinical-stage biopharmaceutical company, which engages in the women's health, clinical development and commercial planning of BP-101, and novel treatment for women with hypoactive sexual desire disorder (HSDD). The firm is developing Orenetide, a novel medicinal treatment for premenopausal women with hypoactive sexual desire disorder (HSDD). The company is focused on women’s health and identifying novel candidates in areas of high unmet medical need. The Company’s lead product, Orenetide (BP-101), is a novel synthetic peptide for the treatment of HSDD and is conveniently administered through a nasal spray. The spray delivers the drug to olfactory and trigeminal nerves in the nasal cavity where the drug accumulates in the olfactory bulb and further in the brain. The company is also developing a new treatment for women affected by low libido or sex drive. The company owns a patent portfolio that provides effective protection of its technology. The firm operates in Ireland, the United Kingdom and Russia.
What is the current price of OVXA stock?
The current stock price of OVXA.I is 0.0105 EUR. The price decreased by -8.7% in the last trading session.
Does OVXA stock pay dividends?
OVXA.I does not pay a dividend.
What is the ChartMill rating of OVOCA BIO PLC stock?
OVXA.I has a ChartMill Technical rating of 1 out of 10 and a ChartMill Fundamental rating of 2 out of 10.
Can you provide the sector and industry classification for OVOCA BIO PLC?
OVOCA BIO PLC (OVXA.I) operates in the Health Care sector and the Pharmaceuticals industry.
What is the market capitalization of OVXA stock?
OVOCA BIO PLC (OVXA.I) has a market capitalization of 928.83K EUR. This makes OVXA.I a Nano Cap stock.